Glasgow, Scotland, United Kingdom – BDD Pharma Ltd, a pharmaceutical company leading expertise in the development and clinical testing of innovative pharmaceutical products, is proud to announce the launch of its new and updated logo for 2023. The new design reflects the company’s commitment to staying at the forefront of the industry and maintaining its position as a global leader in oral drug delivery and clinical testing.
The new logo features a modern and sleek design, with a bold and striking colour scheme that represents the company’s innovative spirit and dedication to quality. It is an update from the previous design, which had been in use for several years. The new logo will be rolled out across all BDD’s marketing materials, digital platforms, including the company’s website and social media channels.
Commenting on the launch of the new logo, Commercial Director Calum Stevens said, “We are excited to unveil our new logo for 2023. Our previous logo has a lot of good will at BDD and a lot of history embedded in it, but it was time for an update. We wanted a design that better reflects our products and services with a modern contemporary look. Our new logo achieves all of that, and we believe it will help us to continue to stand out in a highly competitive industry.”
The launch of the new logo is part of BDD’s ongoing efforts to enhance its brand image and strengthen its position in the global pharmaceutical industry. With a focus on delivering innovative drug delivery products and market leading clinical services that meet the evolving needs of patients and healthcare providers, the company is well-positioned to achieve continued success in the years ahead.
About BDD Pharma Ltd:
BDD Pharma Ltd is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD’s OralogiK™ technology is a tablet-in-tablet drug delivery system providing timed release, targeted release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK™ technology is protected with granted patents across a number of territories including the US, EU and Japan. Supported by investment from Archangels, the Scottish Investment Bank, Alderley Park Ventures and BioCity Investments, BDD has in-house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans.
BDD’s SWIFT adaptive clinical trials integrate formulation development, GMP manufacturing and clinical testing into one streamlined service, offering a more flexible approach than the conventional clinical trial design structure.
BDD Pharma Ltd
+44 (0)141 552 8791